India Pharma Outlook Team | Tuesday, 03 March 2026
Sai Life Sciences is stepping into 2026 riding strong industry momentum as India’s pharma boom drives fresh demand for research, development, and manufacturing services.
The company this year reported solid financial performance with FY 2024-25 revenue of INR 1,731.35 crore, up roughly 16% year-on-year, while profit after tax more than doubled to 170.13 crore, highlighting improved operating strength and growing global engagement.
India’s pharmaceutical sector continues to post strong numbers. Latest government-linked data shows exports climbed 9.4% to about USD 30.47 billion in 2024-25, reflecting surging demand in regulated markets like the US and Europe. Industry analysts project the domestic market to nearly double from USD 60 billion to around USD 130 billion by 2030, underscoring long-term growth potential. India now ranks as the third largest producer of pharmaceuticals by volume with 10,500 manufacturing units and over 3,000 active companies.
Also Read: Role of Wellness in Corporate & Community Health
For Sai Life Sciences, this broader surge translates into expanding business from global clients. The company works with more than 300 international innovators, including 18 of the top 25 global pharma firms, providing end-to-end services from discovery through commercial API manufacturing. Its integrated model is feeding stronger project flows and higher customer retention year after year.
A key data point on capacity expansion is the recent completion of Phase II of Production Block 11 at its Bidar facility in India, boosting total reactor volume to around 700 KL. This makes the site one of the largest manufacturing blocks in Sai’s network, capable of supplying commercial APIs and advanced intermediates into highly regulated markets like the US, EU, and Japan. The facility has passed more than 75 customer audits over the past three years, reinforcing its quality and compliance credentials.
“These are exciting times for all of us at Sai Life Sciences! The investments we have made as part of Sai Nxt are finding resonance with biotech and pharmaceutical innovators globally, especially as our global delivery model is bringing value to our customers through an optimal blend of talent, speed, and cost efficiency.” — Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences.
Sai is also scaling its research capabilities. It recently announced plans to build a new CMC Process R&D Center in Hyderabad that will double its process research capacity, catering to complex molecule development and early clinical supplies. The company has committed to hiring more than 700 scientists and technical professionals in 2026–27 to deepen its talent base and support expanded services.
Beyond growth and operations, Sai Life Sciences released its 2024–25 Sustainability Report, showing progress across climate action, renewable energy, and community engagement. This includes 96% renewable power usage at its Bidar API facility and programs providing education and livelihood opportunities for thousands from underprivileged communities. The report reflects an approach that combines business expansion with long-term environmental and social goals.
Industry data also signals expanding global relevance. India supplies about 40% of the US generic drug market and over 50% of global vaccine demand, and exports pharmaceuticals to more than 200 countries, making the nation a critical hub in global health supply chains. This trend boosts demand for contract research and manufacturing partners like Sai as drug developers seek cost?effective, compliant partners outside China.
With strong execution, expanding capacity, and rising global engagement, Sai Life Sciences is capitalizing on India’s pharma export boom and strengthening its position in the high-growth CRDMO segment. These developments mark 2026 as a year of accelerated scale and deeper industry impact for the company.
Company Performance (Latest FY & Quarter)
India Pharma Industry Stats
